NASDAQ:AGMB AgomAb Therapeutics (AGMB) Stock Price, News & Analysis $5.44 -0.18 (-3.20%) Closing price 03:59 PM EasternExtended Trading$5.43 -0.01 (-0.18%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsSEC FilingsShort Interest About AgomAb Therapeutics Stock (NASDAQ:AGMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AgomAb Therapeutics alerts:Sign Up Key Stats Today's Range$5.39▼$5.7850-Day Range$5.62▼$13.0652-Week Range$5.39▼$17.82Volume181,031 shsAverage Volume155,268 shsMarket Capitalization$197.15 millionP/E RatioN/ADividend YieldN/APrice Target$37.50Consensus RatingModerate Buy Company Overview Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis. Agomab is headquartered in Belgium and is focused on advancing its therapies through clinical development. Its programs are investigational and have not been established as approved treatments.AI Generated. May Contain Errors. Read More AgomAb Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreAGMB MarketRank™: 3.631196932345 of 5 starsAgomAb Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 158th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAgomAb Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialAgomAb Therapeutics has a consensus price target of $37.50, representing about 557.9% upside from its current price of $5.70.Amount of Analyst CoverageAgomAb Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about AgomAb Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AgomAb Therapeutics are expected to decrease in the coming year, from ($1.76) to ($1.97) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.54% of the float of AgomAb Therapeutics has been sold short.Short Interest Ratio / Days to CoverAgomAb Therapeutics has a short interest ratio ("days to cover") of 7.44.Change versus previous monthShort interest in AgomAb Therapeutics has recently decreased by 2.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgomAb Therapeutics does not currently pay a dividend.Dividend GrowthAgomAb Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.26 News SentimentAgomAb Therapeutics has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for AgomAb Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added AgomAb Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of AgomAb Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $577,112.00 in company stock, which represents 0.2794% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, AgomAb Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $577,112.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsAgomAb Therapeutics has minimal institutional ownership at this time.Read more about AgomAb Therapeutics' insider trading history. Receive AGMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AgomAb Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGMB Stock News HeadlinesAgomAb Therapeutics (NASDAQ:AGMB) Director Acquires 5,000 Shares of Company StockNovember 20 at 7:37 AM | insidertrades.comHC Wainwright Has Positive Opinion of AGMB FY2026 EarningsNovember 20 at 1:58 AM | americanbankingnews.comA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.November 20 at 1:00 AM | Monetary Gold (Ad)Insider Buying: AgomAb Therapeutics (NASDAQ:AGMB) Director Buys $88,681.60 in StockNovember 17 at 4:37 AM | insidertrades.comAgomAb Therapeutics (NASDAQ:AGMB) Director David Epstein Buys 15,000 Shares of StockNovember 7, 2026 | insidertrades.comAgomab to Participate in Upcoming Investor ConferencesNovember 4, 2026 | globenewswire.comAgomAb Therapeutics (NASDAQ:AGMB) Director Buys 10,000 Shares of Company StockOctober 23, 2026 | insidertrades.comAgomab Doses First Patient In Phase 2b Ontunisertib Trial For Crohn's DiseaseOctober 14, 2026 | rttnews.comSee More Headlines AGMB Stock Analysis - Frequently Asked Questions How have AGMB shares performed this year? AgomAb Therapeutics' stock was trading at $15.15 on February 17, 2026. Since then, AGMB shares have decreased by 62.4% and is now trading at $5.70. When did AgomAb Therapeutics IPO? AgomAb Therapeutics (AGMB) raised $200 million in an initial public offering on Friday, February 6th 2026. The company issued 12,500,000 shares at $15.00-$17.00 per share. How do I buy shares of AgomAb Therapeutics? Shares of AGMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AGMB CIK2020932 Webwww.agomab.com Phone(323) 302-3530FaxN/AEmployees62Year Founded2017Price Target and Rating Average Price Target for AgomAb Therapeutics$37.50 High Price Target$60.00 Low Price Target$28.00 Potential Upside/Downside+582.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio12.88 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares36,240,000Free FloatN/AMarket Cap$198.99 million OptionableN/A BetaN/A The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:AGMB) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AgomAb Therapeutics NV Please log in to your account or sign up in order to add this asset to your watchlist. Share AgomAb Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.